Table 2. Proposed target product profiles for diagnostic tools for selected NTDs, post-elimination surveillance.^a .

Characteristic	Lymphatic Filariasis	Trachoma	Schistosomiasis	Onchocerciasis
Intended use	Post-elimination incidence of infection	Post-elimination incidence of infection	Post-elimination incidence of infection	Post-elimination incidence of infection
Possible target population	Children born after transmission interruption	Children born after transmission interruption	Children born after transmission interruption	Children born after transmission interruption
Possible sample types	Blood spot	Blood spot	Blood spot or urine (avoid stool if possible)	Blood spot
Ideal diagnostic marker	Antibody	Antibody to a conserved species-specific epitope of MOMP	Antibody	Ov16 antibody
Availability of ideal diagnostic marker	Not available	Libraries available	In development	Available, but additional validation needed
Ideal test format	High throughput laboratory assay	High throughput laboratory assay	High throughput laboratory assay	High throughput laboratory assay
Population infection thresholds (for stopping MDA)	1%	Not defined	10% of school-aged children	1/3,000
Probable sampling strategy	PBPS	PBPS	PBPS or school surveys (or sentinel occupations)	PBPS

^aSchistosomiasis is included in this table because several countries have programmes to eliminate this disease [18], [19]. The soil-transmitted helminth infections are not included because (as for schistosomiasis in most endemic states) the current goal is prevention of morbidity in school-aged children through periodic high-coverage MDA.

ICT, immunochromatographic card test; LF, lymphatic filariasis; MDA, mass drug administration; MOMP, major outer membrane protein of C. trachomatis; NTDs, neglected tropical diseases; PBPS, population-based prevalence survey.